Patent · US Active

Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide

US10105447B2 · kind B2 · utility

0Cited by

0References

5Claims

0Family size

Assignees

Elanco US Inc. · US
Ambrx, Inc. · US

Inventors

Michael Bledsoe · San Diego, US
Peter C. Canning · Noblesville, US
Michael Deguzman · San Diego, US
Nick Knudsen · San Diego, US
Ianina Valenta · Village of La Jolla, US

Key dates

Filing date	Mar 12, 2014
Grant date	Oct 23, 2018
Priority date	—
Expiry date	Mar 12, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/5759
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Modified canine leptin polypeptides and formulations and uses thereof, are provided including polyethylene glycol (PEG) modified canine leptin polypeptides, wherein the PEG moiety is covalently attached to a para-acetyl-phenylalanine (pAF) residue of the polypeptide, and related compositions and methods useful in treating companion animal obesity and other leptin-related disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.